Novo Nordisk <NOVOb.CO> said on Friday Britain's cost-effectiveness watchdog would recommend the Danish drugmaker's newest diabetes drug Victoza in 1.2 mg doses for the treatment of type 2 diabetes.

The Novo Nordisk combo of liraglutide and insulin degludec in a single-injection delivery device is a good option for type 2 patients not controlled on oral agents and basal insulin, new data show.

Danish group Novo Nordisk's diabetes drug Victoza has a 43 percent chance of being approved as an obesity treatment in the United States, according to a Reuters poll which found Danish bank ...